eMedicine Specialties > Neurology > Neurological Infections

Neurocysticercosis

Author: Mohammed J Zafar, MD, FAAN, Associate Clinical Professor of Medicine, Kalamazoo Center for Medical Studies, Michigan State University; NeuroImager, Premier Medical Care, PC, Premier Radiology, Kalamazoo Neurologic Institute.
Contributor Information and Disclosures

Updated: Jul 1, 2009

Introduction

Background

Neurocysticercosis (NCC) is the most common parasitic disease of the nervous system and is the main cause of acquired epilepsy in developing countries. Lately, it has also been a problem in industrialized countries because of immigration of tapeworm carriers from areas of endemic disease.

See also, eMedicine article Neuroimaging in Neurocysticercosis.

Pathophysiology

NCC is the result of accidental ingestion of eggs of Taenia solium (ie, pork tapeworm), usually due to contamination of food by people with teniasis. T solium has a two-host biological cycle, with man as the definitive host carrying the intestinal tapeworm, and pig as the normal intermediate host harboring the larvae or cysticerci. It has a head (scolex) with 4 suckers and a double crown of hooks, an unsegmented neck, and a large body with several hundreds of hermaphrodite proglottids.

Cysticerci are ingested by humans through poorly cooked infected pork. Cysts evaginate in the small intestine, attach to the wall by its suckers and hooks, and develop strobila or chains of proglottids. From the distal end of the strobila, fertile eggs are excreted into the gravid proglottids. Up to 60,000 eggs may be contained in a proglottid. Pigs ingest stool contaminated with Taenia eggs, the embryos actively cross the intestinal wall, get into the bloodstream, and are transported to most tissues, where they reside as cysticerci. Larvae are found most commonly in the CNS, but they can also be located in the eye, muscle, or subcutaneous or other tissues.

Frequency

United States

NCC is mainly a disease of immigrants in the United States. Currently the disease is prevalent in the states of California, Texas, and New Mexico. It represents a major cause of morbidity among the Hispanic population. Most of the cases have been diagnosed in persons of Hispanic origin; however, because of travel to zones of endemic disease, the incidence is increasing in nonendemic countries. Native cases have been reported, presumably because of ingestion of infected food that was handled by carriers of T solium.

International

NCC is endemic in Central and South America, sub-Saharan Africa, and in some regions of the Far East, including the Indian subcontinent, Indonesia, and China, reaching an incidence of 3.6% in some regions. It is rare in Eastern and Central Europe, in North America (with the exception of Mexico), and in Australia, Japan, and New Zealand, as well as in Israel and in the Muslim countries of Africa and Asia. Cysticercosis can be seen in immigrant populations with a relatively high frequency, as in the southwest of United States and South Africa. NCC is the most common parasitic infection of the CNS. Approximately 2.5 million people worldwide carry the adult tapeworm, and many more are infected with cysticerci.

Mortality/Morbidity

No figures are available for the burden of mortality associated with NCC. However, the racemose1 form of NCC, which appears macroscopically as groups of cysticerci, often in clusters that resemble bunches of grapes (see Media file 1), located in the subarachnoid space, is associated with poor prognosis and elevated mortality rate (over 20%). NCC-associated epilepsy is an important cause of neurological morbidity.2

Massive nonencephalitic neurocysticercosis. Photo...

Massive nonencephalitic neurocysticercosis. Photo courtesy of Cysticercosis Working Group in Peru.

Massive nonencephalitic neurocysticercosis. Photo...

Massive nonencephalitic neurocysticercosis. Photo courtesy of Cysticercosis Working Group in Peru.

Race

Subcutaneous cysticercosis is more common in Asian populations than in other peoples of other areas of endemic disease. It is not clear whether this is due to variations in parasite strain or to those in the host.

Sex

  • NCC appears to affect men and women equally.
  • Some evidence suggests that inflammation around parasites may be more severe in women than in men.3

Age

  • Peak incidence is between ages 30 and 40 years.
  • Although neurocysticercosis appears to be the most frequent cause of seizures in children4 and adults, the exact incidence in children is not known. The disease is increasingly commonly diagnosed with the routine use of diagnostic methods such as computed tomography (CT) and magnetic resonance imaging (MRI) of the brain.

Clinical

History

NCC is a pleomorphic disease, although it sometimes produces no clinical manifestation. This pleomorphism is due to variations in the locations of the lesions, the number of parasites, and the host's immune response.

  • Many patients are asymptomatic; others report vague symptoms such as headache or dizziness.
  • The onset of symptoms is usually subacute to chronic, with the exception of seizures, which present in an acute fashion. Patients may present with the following:
    • Epilepsy
      • Epilepsy is the most common presentation (70%) and is also a complication of the disease.2
      • NCC is the leading cause of adult-onset epilepsy and is probably one of the most frequent causes of childhood epilepsy in the world.
      • Seizures secondary to NCC may be generalized or partial. Simple and complex partial seizures may be associated with the presence of a single lesion. Generalized seizures are usually tonic-clonic; this is thought to be related to the presence of multiple lesions. However, irritation of focal cortical tissue by one of the lesions most probably leads to focal onset with secondary generalization. Myoclonic seizures also have been described.
    • Headache
      • Chronic headaches associated with nausea and vomiting (simulating migraines) 
      • Headaches associated with intracranial hypertension and indicative of hydrocephalus
      • Headaches due to meningitis
    • Intracranial hypertension
      • Most often, intracranial hypertension is due to obstruction of cerebrospinal fluid (CSF) circulation caused by basal or ventricular cysticercosis. It may also result from large cysts displacing midline structures, granular ependymitis, arachnoiditis, or the so-called cysticercotic encephalitis caused by the inflammatory response to a massive infestation of cerebral parenchyma with cysticerci.
      • These patients may have seizures and deterioration of their mental status, mainly due to the host's inflammatory reaction as an exaggerated response to the massive infestation.
    • Strokes5
      • Ischemic cerebrovascular complications of NCC include lacunar infarcts6 and large cerebral infarcts due to occlusion or vascular damage.
      • Hemorrhage also can occur, and has been reported as a result of rupture of mycotic aneurysms of the basilar artery.
      • Strokes may be responsible for the following signs and symptoms: paresis or plegias, involuntary movements, gait disturbances, or paresthesias.
    • Neuropsychiatric disturbances
      • These range from poor performance on neuropsychological tests to severe dementia.
      • These symptoms appear to be related more to the presence of intracranial hypertension than to the number or location of parasites in the brain.
    • Diplopia: This is a result of intracranial hypertension or arachnoiditis producing entrapment or compression of cranial nerves III, IV, or VI.
    • Hydrocephalus
      • Ten to thirty percent of patients with NCC develop communicating hydrocephalus due to inflammation and fibrosis of the arachnoid villi or inflammatory reaction to the meninges and subsequent occlusion of the foramina of Luschka and Magendie.
      • Noncommunicating hydrocephalus may be a consequence of intraventricular cysts.
  • Other forms of neurocysticercosis
    • Intrasellar neurocysticercosis: Patients present with ophthalmologic and endocrinologic manifestations mimicking those of pituitary tumors.
    • Spinal NCC: This is rare. Spinal NCC may be either intramedullary or extramedullary. The latter is the most frequent and is responsible of symptoms of spinal dysfunction such as radicular pain, weakness, and paresthesias. Intramedullary presentation may cause paraparesis, sensory deficits with a level, and sphincter disturbances.
    • Ocular cysticercosis: This occurs most commonly in the subretinal space. Patients may present with decreased visual acuity, visual field defects, or monocular blindness.
    • Systemic cysticercosis: This is most common in the Asian continent. The parasites may be located in the subcutaneous tissue or muscle. Peripheral nerve involvement as well as involvement of liver or spleen have been reported.

Physical

Twenty percent or less of infected patients have abnormal neurological findings. Physical findings will depend on where the cyst is located in the nervous system and include the following:

  • Cognitive decline
  • Dysarthria
  • Extraocular movement palsy or paresis
  • Hemiparesis or hemiplegia, which may be related to stroke, or Todd paralysis
  • Hemisensory loss
  • Movement disorders
  • Hyper/hyporeflexia
  • Gait disturbances
  • Meningeal signs

Causes

NCC can be acquired via fecal-oral contact with carriers of the adult tapeworm. This usually indicates the presence of a tapeworm carrier in the immediate environment (ie, household) or by accidental ingestion of contaminated food. Cases of autoingestion, in which persons with teniasis may ingest the eggs of T solium into their intestine, have been reported.

More on Neurocysticercosis

Overview: Neurocysticercosis
Differential Diagnoses & Workup: Neurocysticercosis
Treatment & Medication: Neurocysticercosis
Follow-up: Neurocysticercosis
Multimedia: Neurocysticercosis
References

References

  1. Bickerstaff ER, Cloake PC, Hughes B, Smith WT. The racemose form of cerebral cysticercosis. Brain. Mar 1952;75(1):1-18. [Medline].

  2. Del Brutto OH, Santibanez R, Noboa CA, et al. Epilepsy due to neurocysticercosis: analysis of 203 patients. Neurology. Feb 1992;42(2):389-92. [Medline].

  3. Del Brutto OH, Garcia E, Talamas O, Sotelo J. Sex-related severity of inflammation in parenchymal brain cysticercosis. Arch Intern Med. Mar 1988;148(3):544-6. [Medline].

  4. Gaffo AL, Guillen-Pinto D, Campos-Olazabal P, Burneo JG. [Cysticercosis as the main cause of partial seizures in children in Peru]. Rev Neurol. Nov 16-30 2004;39(10):924-6. [Medline].

  5. Barinagarrementeria F, Cantu C. Neurocysticercosis as a cause of stroke. Stroke. Aug 1992;23(8):1180-1. [Medline].

  6. Barinagarrementeria F, Del Brutto OH. Lacunar syndrome due to neurocysticercosis. Arch Neurol. Apr 1989;46(4):415-7. [Medline].

  7. Garcia HH, Martinez SM. Taenia solium/cysticercosis. Lima: Editorial Universo. 1999.

  8. Garcia HH, Pretell EJ, Gilman RH, et al. A trial of antiparasitic treatment to reduce the rate of seizures due to cerebral cysticercosis. N Engl J Med. Jan 15 2004;350(3):249-58. [Medline].

  9. Garg RK. Medical management of neurocysticercosis. Neurol India. Dec 2001;49(4):329-37. [Medline].

  10. Sotelo J, Escobedo F, Penagos P. Albendazole vs praziquantel for therapy for neurocysticercosis. A controlled trial. Arch Neurol. May 1988;45(5):532-4. [Medline].

  11. Proano JV, Madrazo I, Avelar F, et al. Medical treatment for neurocysticercosis characterized by giant subarachnoid cysts. N Engl J Med. Sep 20 2001;345(12):879-85. [Medline].

  12. Bittencourt PR, Gracia CM, Martins R, et al. Phenytoin and carbamazepine decreased oral bioavailability of praziquantel. Neurology. Mar 1992;42(3 Pt 1):492-6. [Medline].

  13. Boecher-Schwarz HG, Hey O, Higer HP, Perneczky A. Intrasellar cysticercosis mimicking a pituitary adenoma. Br J Neurosurg. 1991;5(4):405-7. [Medline].

  14. Cardenas F, Quiroz H, Plancarte A, et al. Taenia solium ocular cysticercosis: findings in 30 cases. Ann Ophthalmol. Jan 1992;24(1):25-8. [Medline].

  15. Carpio A, Placencia M, Santillan F, Escobar A. A proposal for classification of neurocysticercosis. Can J Neurol Sci. Feb 1994;21(1):43-7. [Medline].

  16. Case records of the Massachusetts General Hospital. Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 26-1994. A 20-year-old Philippine woman with a soft-tissue mass in the forearm. N Engl J Med. Jun 30 1994;330(26):1887-93. [Medline].

  17. Del Brutto OH. [Neurocisticercosis]. 1998;[Full Text].

  18. del Brutto OH. [Neurocysticercosis]. Rev Neurol. Sep 1-15 1999;29(5):456-66. [Medline].

  19. [Best Evidence] Del Brutto OH, Roos KL, Coffey CS, Garcia HH. Meta-analysis: Cysticidal drugs for neurocysticercosis: albendazole and praziquantel. Ann Intern Med. Jul 4 2006;145(1):43-51. [Medline].

  20. Del Brutto OH, Sotelo J, Roman GC. Neurocysticercosis: A Clinical Handbook. Vol 1. Lisse: Swets & Zeitlinger;1988.

  21. Garcia HH, Del Brutto OH. Heavy nonencephalitic cerebral cysticercosis in tapeworm carriers. The Cysticercosis Working Group in Perú. Neurology. Oct 22 1999;53(7):1582-4. [Medline].

  22. Garcia HH, Gilman R, Martinez M, et al. Cysticercosis as a major cause of epilepsy in Peru. The Cysticercosis Working Group in Peru (CWG). Lancet. Jan 23 1993;341(8839):197-200. [Medline].

  23. Garcia HH, Gilman RH, Gonzales AE. Epidemiology of Tenia solium infection in Peru. Cysticercosis Working Group Peru. In: Garcia HH, Martinez SM. Taenia Solium Taeniasis/Cysticercosis. 1999:297-305.

  24. Garg RK. Neurocysticercosis. Postgrad Med J. Jun 1998;74(872):321-6. [Medline].

  25. Gemmel M, Matyas Z, Pawlosky Z. Guidelines for surveillance, prevention and control of taeniasis/cysticercosis. Geneva: WHO. 1983.

  26. Grisolia JS, Wiederholt WC. CNS cysticercosis. Arch Neurol. Sep 1982;39(9):540-4. [Medline].

  27. Isidro-Llorens A, Dachs F, Vidal J, Sarrias M. Spinal cysticercosis. Case report and review. Paraplegia. Feb 1993;31(2):128-30. [Medline].

  28. Lopez-Hernandez A, Garaizar C. Childhood cerebral cysticercosis: clinical features and computed tomographic findings in 89 Mexican children. Can J Neurol Sci. Nov 1982;9(4):401-7. [Medline].

  29. Miller BL, Staugaitis SM, Tourtellotte WW, et al. Intra-blood-brain barrier IgG synthesis in cerebral cysticercosis. Arch Neurol. Aug 1985;42(8):782-4. [Medline].

  30. Monteiro L, Coelho T, Stocker A. Neurocysticercosis--a review of 231 cases. Infection. Mar-Apr 1992;20(2):61-5. [Medline].

  31. Puri V, Chowdhury V, Gulati P. Myoclonus: a manifestation of neurocysticercosis. Postgrad Med J. Jan 1991;67(783):68-9. [Medline].

  32. Sotelo J, Guerrero V, Rubio F. Neurocysticercosis: a new classification based on active and inactive forms. A study of 753 cases. Arch Intern Med. Mar 1985;145(3):442-5. [Medline].

  33. Soto-Hernandez JL, Gomez-Llata Andrade S, Rojas-Echeverri LA, et al. Subarachnoid hemorrhage secondary to a ruptured inflammatory aneurysm: a possible manifestation of neurocysticercosis: case report. Neurosurgery. Jan 1996;38(1):197-9; discussion 199-200. [Medline].

  34. Wallin MT, Kurtzke JF. Neurocysticercosis in the United States: review of an important emerging infection. Neurology. Nov 9 2004;63(9):1559-64. [Medline].

  35. White AC. Neurocysticercosis: a major cause of neurological disease worldwide. Clin Infect Dis. Feb 1997;24(2):101-13; quiz 114-5. [Medline].

Further Reading

Keywords

NCC, parasitic disease, cerebral cysticercosis, Taenia solium, taeniasis, tapeworm, teniasis, pork tapeworm, cysticerci, subcutaneous cysticercosis, epilepsy, seizures, subarachnoid cysticercosis

Contributor Information and Disclosures

Author

Mohammed J Zafar, MD, FAAN, Associate Clinical Professor of Medicine, Kalamazoo Center for Medical Studies, Michigan State University; NeuroImager, Premier Medical Care, PC, Premier Radiology, Kalamazoo Neurologic Institute.
Mohammed J Zafar, MD, FAAN is a member of the following medical societies: American Academy of Neurology, American Medical Association, American Society of Neuroimaging, and Michigan State Medical Society
Disclosure: Nothing to disclose.

Medical Editor

Amy A Pruitt, MD, Associate Professor of Neurology, University of Pennsylvania; Attending Neurologist, Hospital of the University of Pennsylvania
Amy A Pruitt, MD is a member of the following medical societies: American Academy of Neurology
Disclosure: Nothing to disclose.

Pharmacy Editor

Francisco Talavera, PharmD, PhD, Senior Pharmacy Editor, eMedicine
Disclosure: eMedicine Salary Employment

Managing Editor

Florian P Thomas, MD, MA, PhD, Drmed, Director, Spinal Cord Injury Unit, St Louis Veterans Affairs Medical Center; Director, National MS Society Multiple Sclerosis Center; Professor, Department of Neurology and Psychiatry, Associate Professor, Institute for Molecular Virology, and Department of Molecular Microbiology and Immunology, St Louis University
Florian P Thomas, MD, MA, PhD, Drmed is a member of the following medical societies: American Academy of Neurology, American Paraplegia Society, and National Multiple Sclerosis Society
Disclosure: Nothing to disclose.

CME Editor

Selim R Benbadis, MD, Professor, Director of Comprehensive Epilepsy Program, Departments of Neurology and Neurosurgery, University of South Florida School of Medicine, Tampa General Hospital
Selim R Benbadis, MD is a member of the following medical societies: American Academy of Neurology, American Academy of Sleep Medicine, American Clinical Neurophysiology Society, American Epilepsy Society, and American Medical Association
Disclosure: Nothing to disclose.

Chief Editor

Nicholas Y Lorenzo, MD, Chief Editor, eMedicine Neurology; Consulting Staff, Neurology Specialists and Consultants
Nicholas Y Lorenzo, MD is a member of the following medical societies: Alpha Omega Alpha and American Academy of Neurology
Disclosure: Nothing to disclose.

 
 
HONcode

We subscribe to the
HONcode principles of the
Health On the Net Foundation

All material on this website is protected by copyright, Copyright© 1994- by Medscape.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.